Welcome to our dedicated page for Novo-Nordisk A S SEC filings (Ticker: NONOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for NOVO NORDISK A/S B NEW (NONOF) provides access to disclosures filed by Novo Nordisk A/S as a foreign issuer. These filings give detailed insight into the company that underlies NONOF, including its therapeutic focus, clinical programmes, governance decisions and insider transactions.
Through Form 6-K and other submissions, Novo Nordisk reports material developments such as FDA approval of the Wegovy pill, a once-daily oral semaglutide 25 mg tablet for weight management and reduction of major adverse cardiovascular events in adults with obesity or overweight and specific cardiovascular conditions. Filings also describe the OASIS phase 3 programme in obesity, phase 2 results for amycretin in type 2 diabetes, and outcomes of the evoke and evoke+ phase 3 trials in Alzheimer’s disease.
Regulatory documents further cover corporate matters. Extraordinary general meeting resolutions detail changes in the Board of Directors and the composition of committees like the Audit, Remuneration, People and Governance, and Research & Development Committees. Separate filings disclose trading in Novo Nordisk shares by board members, executives and associated persons, in line with market abuse rules, providing transparency around insider activity in Novo Nordisk B shares listed on Nasdaq Copenhagen and ADRs listed on the New York Stock Exchange.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain the key points in plain language. Users researching NONOF can use this page to quickly understand what Novo Nordisk reports in its official documents, from clinical data and product approvals to governance changes and insider transactions, without reading every page of each filing.
Novo Nordisk reported top-line results from its evoke and evoke+ phase 3 trials testing oral semaglutide in early-stage symptomatic Alzheimer’s disease. Across 3,808 adults, semaglutide did not show superiority to placebo in slowing disease progression as measured by change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) over two years. Although Alzheimer’s-related biomarkers improved, this did not translate into a clinical benefit.
Semaglutide’s safety and tolerability in patients aged 55–85 with mild cognitive impairment or mild dementia due to Alzheimer’s disease were consistent with previous semaglutide studies, which together represent more than 37 million patient-years of exposure. Based on these efficacy results, the 1‑year extension phase of the evoke and evoke+ trials will be discontinued. Novo Nordisk emphasized that semaglutide remains an important treatment for type 2 diabetes, obesity and related conditions.
Novo Nordisk A/S has reported insider dealing information in line with market abuse regulations. The company discloses that board member Stephan Engels purchased Novo Nordisk B shares on Nasdaq Copenhagen. He bought 6,450 shares at a price of DKK 312.50 per share, corresponding to an aggregated transaction value of DKK 2,015,625.00 on 17 November 2025. The report is made under Article 19 of EU Regulation No. 596/2014 on market abuse, which requires company insiders and their closely associated persons to notify transactions in the company’s shares.
Novo Nordisk A/S held an Extraordinary General Meeting on 14 November 2025 to refresh its Board of Directors. Helge Lund, Henrik Poulsen and five other members stepped down. Shareholders elected Lars Rebien Sørensen as chair and Cees de Jong as vice chair, with Britt Meelby Jensen and Stephan Engels joining as members.
All elections run until the next Annual General Meeting on 26 March 2026. Following the meeting, committee roles were set: Sørensen will chair the People and Governance Committee; de Jong will chair the Remuneration Committee and serve on Audit; Engels will chair Audit and sit on Remuneration and People and Governance; and Kasim Kutay will chair the Research & Development Committee.
Novo Nordisk A/S announced that Mikael Dolsten will not seek election to its Board at the extraordinary general meeting on 14 November 2025. Dolsten, formerly Head of R&D at Pfizer, withdrew his candidacy as member and observer due to recent personal circumstances unrelated to Novo Nordisk or the Novo Nordisk Foundation.
The Novo Nordisk Foundation and Novo Holdings A/S will not propose a replacement at the meeting. Instead, they intend for the incoming Board to nominate two additional candidates, alongside the already nominated Helena Saxon, for election at the Annual General Meeting on 26 March 2026. Other candidates for the 14 November 2025 meeting remain as previously announced.
Novo Nordisk A/S reported insider dealings under Article 19 of the EU Market Abuse Regulation. The company disclosed transactions by David Moore, Executive Vice President, US Operations, in Novo Nordisk B shares.
On 2025-11-10, Moore completed two transactions: an acquisition of 18,634 shares at DKK 0.00 as part of a recruitment package (outside a trading venue), and a sale of 8,160 shares at DKK 297.95 on Nasdaq Copenhagen, for an aggregated amount of DKK 2,431,301.74. The instrument is identified as Novo Nordisk B (ISIN DK0062498333).
These disclosures are routine for board members and executives and are reported to enhance transparency around trading by persons discharging managerial responsibilities and their associated persons.
Novo Nordisk announced an agreement with the U.S. Administration to lower prices for semaglutide medicines, including Wegovy and Ozempic, and expand access in the U.S. starting in 2026. Coverage for anti-obesity medicines will be enabled in Medicare Part D through a pilot program designed to cover a majority of Part D beneficiaries. Prices will also be lowered in Medicaid and in the direct-to-patient cash channel, and the company is expected to receive a three-year tariff exemption.
Novo Nordisk currently expects an estimated direct, negative low single-digit impact on global sales growth in 2026. The company plans to provide its 2026 financial outlook alongside full-year 2025 results on 4 February 2026. Following this announcement, Novo Nordisk and the U.S. Administration will finalize the agreement’s details.
Novo Nordisk reported solid growth for the first nine months of 2025 while absorbing major restructuring costs and tightening its outlook. Net sales rose 12% in Danish kroner to DKK 229.9 billion, or 15% at constant exchange rates, driven mainly by Diabetes and Obesity care. Operating profit increased 5% to DKK 95.9 billion (10% at CER), but included around DKK 9 billion of one-off restructuring costs tied to a company-wide transformation; excluding these, operating profit would have grown 15% in kroner and 21% at CER. Net profit was DKK 75.5 billion, up 4%, and diluted EPS reached DKK 16.99.
Obesity care sales climbed 37% in kroner to DKK 59.9 billion (41% at CER), powered by Wegovy, while GLP‑1 diabetes products grew 10% at CER to DKK 114.7 billion. Rare disease sales rose 13% at CER to DKK 14.3 billion. The company is cutting about 9,000 of 78,400 positions and redirecting savings into growth areas.
Novo Nordisk now expects 2025 sales growth of 8–11% at CER and operating profit growth of 4–7% at CER, narrowing prior ranges and reflecting lower growth expectations for GLP‑1 treatments, ongoing transformation costs and recent acquisitions. The R&D pipeline advanced with an FDA approval for Wegovy in MASH, new cardiovascular indications for Rybelsus, multiple late‑stage obesity programmes and the planned acquisition of Akero Therapeutics to expand its MASH portfolio.
Novo Nordisk (NVO) announced an unsolicited proposal to acquire Metsera, Inc. The offer includes cash consideration of 56.50 USD per share, equal to an approximate aggregated equity value of 6.5 billion USD (approximate enterprise value of 6.0 billion USD), plus contingent value rights (CVRs) of up to 21.25 USD per share (an approximate aggregated value of up to 2.5 billion USD) tied to clinical and regulatory milestones.
The cash consideration would be paid at signing in exchange for non‑voting preferred stock representing 50% of Metsera’s share capital, and the CVRs would be issued at closing in exchange for the remaining shares. Novo Nordisk states that Metsera’s early and development‑stage incretin and non‑incretin peptide programs are complementary to its strategy in obesity and diabetes. The proposal is subject to review by Metsera’s board.
Novo Nordisk A/S called a fully electronic Extraordinary General Meeting to elect new members to the Board of Directors. The meeting will be held on 14 November 2025 at 14:00 CET.
The agenda proposes electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and Britt Meelby Jensen, Mikael Dolsten and Stephan Engels as board members, with Kasim Kutay continuing. Several current directors will not stand for election. All proposals may be adopted by a simple majority of votes.
Record date for participation and voting rights is 7 November 2025 at 23:59 CET. Registration and proxy deadlines are 10 November 2025 at 23:59 CET, and votes by correspondence must be received by 13 November 2025 at 09:00 CET. The Company’s share capital is DKK 446,500,000, split into A shares DKK 107,487,200 (10 votes per DKK 0.01) and B shares DKK 339,012,800 (1 vote per DKK 0.01).
Novo Nordisk A/S will convene an Extraordinary General Meeting to elect new members of the Board of Directors on 14 November 2025. The decision follows dialogue with the Novo Nordisk Foundation about board composition; the Foundation holds the majority of votes. The Board concluded that electing new members via an EGM is in the best interest of the company and shareholders to provide clarity on future governance.
Chair Helge Lund, Vice Chair Henrik Poulsen, and independent directors Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the EGM. Kasim Kutay (not independent) and employee‑elected members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board.
Novo Nordisk will host an investor conference call at 15:00 CEST on 21 October 2025, with a dial‑in link available on the company’s investor website.